{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:08:25Z","timestamp":1776989305298,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ygyno.2020.08.016","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T12:36:31Z","timestamp":1600691791000},"page":"581-587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer"],"prefix":"10.1016","volume":"159","author":[{"given":"Cortney M.","family":"Eakin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor J.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana M.","family":"Chase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ygyno.2020.08.016_bb0005","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer."},{"issue":"6","key":"10.1016\/j.ygyno.2020.08.016_bb0010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","article-title":"Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea?","volume":"20","author":"Ng","year":"2015","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ygyno.2020.08.016_bb0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2020.08.016_bb0020","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bjc.2016.348","article-title":"Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer","volume":"115","author":"Ledermann","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2020.08.016_bb0025","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.08.016_bb0030","article-title":"NCCN clinical practice guidelines in oncology: Antiemesis version 2","author":"Ettinger","year":"2020","journal-title":"Natl. Compr. Cancer Care Netw."},{"issue":"12","key":"10.1016\/j.ygyno.2020.08.016_bb0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JOP.2017.026351","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"13","author":"Hesketh","year":"2017","journal-title":"J. Oncol. Pract."},{"issue":"Suppl. 5","key":"10.1016\/j.ygyno.2020.08.016_bb0040","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.016_bb0045","series-title":"MASSC\/ESMO Antiemetic Guideline 2016 with Updates in 2019","author":"Aapro","year":"2019"},{"issue":"14","key":"10.1016\/j.ygyno.2020.08.016_bb0050","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting","volume":"374","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.08.016_bb0055","article-title":"Prevention of nausea and vomiting in patients undergoing oral anticancer therapies for solid tumors","volume":"309601","author":"Costa","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ygyno.2020.08.016_bb0060","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2147\/DDDT.S164553","article-title":"Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials","volume":"12","author":"Liu","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"8","key":"10.1016\/j.ygyno.2020.08.016_bb0065","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2015-0268","article-title":"Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer","volume":"21","author":"Moore","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2020.08.016_bb0070","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.08.016_bb0075","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2020.08.016_bb0080","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2020.08.016_bb0085","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10106","key":"10.1016\/j.ygyno.2020.08.016_bb0090","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ygyno.2020.08.016_bb0095","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2020.08.016_bb0100","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.08.016_bb0105","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","author":"Gonzalez-Martin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2020.08.016_bb0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.016_bb0115","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.08.016_bb0120","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2017.05.029","article-title":"Ovarian cancer survivors\u2019 acceptance of treatment side effects evolves as goals of care change over the cancer continuum","volume":"146","author":"Frey","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.016_bb0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.08.012","article-title":"FDA ovarian cancer clinical trial endpoints workshop: a Society of Gynecologic Oncology White Paper","volume":"147","author":"Herzog","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.08.016_bb0130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.COC.0000027269.06091.E9","article-title":"Melphalan for the treatment of patients with recurrent epithelial ovarian cancer","volume":"26","author":"Davis-Perry","year":"2003","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.016_bb0135","series-title":"Lynparza (Olaparib) Capsules [Prescribing Information]","author":"AstraZeneca Pharmaceuticals","year":"2017"},{"key":"10.1016\/j.ygyno.2020.08.016_bb0140","series-title":"Rubraca (Rucaparib) Tablets [Prescribing Information]","author":"Clovis Oncology Inc","year":"2016"},{"key":"10.1016\/j.ygyno.2020.08.016_bb0145","series-title":"Zejula (Niraparib) Capsules [Prescribing Information]","author":"Tesaro Inc","year":"2017"},{"key":"10.1016\/j.ygyno.2020.08.016_bb0150","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00520-014-2400-3","volume":"23","author":"Raftopoulos","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2020.08.016_bb0155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00520-015-2865-8","article-title":"Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study","volume":"24","author":"Seol","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2020.08.016_bb0160","article-title":"A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation [published online ahead of print, 2020 Apr 27]","author":"Armbruster","year":"2020","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2020.08.016_bb0165","article-title":"Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults","volume":"9","author":"Sutherland","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"10.1016\/j.ygyno.2020.08.016_bb0170","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"21","author":"Navari","year":"2013","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2020.08.016_bb0175","first-page":"1","article-title":"Olanzapine for the treatment of advanced Cancer-related chronic nausea and\/or vomiting: a randomized pilot trial [published online ahead of print, 2020 may 7]","volume":"6","author":"Navari","year":"2020","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.08.016_bb0180","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2018.01.010","article-title":"Management of the toxicities of common targeted therapeutics for gynecologic cancers","volume":"148","author":"Gunderson","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.016_bb0185","author":"National Comprehensive Care Network"},{"key":"10.1016\/j.ygyno.2020.08.016_bb0190","author":"National Cancer Institute"},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.016_bb0195","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1634\/theoncologist.2019-0229","article-title":"Real-world delivery of Rucaparib to patients with ovarian cancer: recommendations based on an integrated safety analysis of ARIEL2 and study 10","volume":"25","author":"Drew","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ygyno.2020.08.016_bb0200","article-title":"Managing nausea and vomiting in patients with cancer: what works","volume":"32","author":"Navari","year":"2018","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"10.1016\/j.ygyno.2020.08.016_bb0205","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1097\/NCC.0b013e3181e2cd79","article-title":"Tools for assessing nausea, vomiting, and retching","volume":"34","author":"Wood","year":"2011","journal-title":"Cancer Nurs."},{"issue":"2","key":"10.1016\/j.ygyno.2020.08.016_bb0210","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jpainsymman.2006.10.018","article-title":"Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis tool","volume":"34","author":"Molassiotis","year":"2007","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.ygyno.2020.08.016_bb0215","series-title":"Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","first-page":"67","volume":"vol. 36","author":"Kluetz","year":"2016"},{"key":"10.1016\/j.ygyno.2020.08.016_bb0220","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0","author":"National Cancer Institute","year":"2017"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820338178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820338178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T08:04:25Z","timestamp":1715846665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820338178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0090825820338178"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}